As the leading Pan-European marketplace, Euronext’s ambition is to serve the real economy by bringing together buyers and sellers in venues that are transparent, efficient and reliable. Our roots are deep: for four centuries, the exchanges that now comprise Euronext have been at the heart of European capital markets. Today Europe enters a new cycle in which regulated markets will play an increasingly significant role. Amid rising demand for new and diverse sources of capital and solutions for the transfer of risk, and growing pressure for more transparency and supervision, Euronext’s unique portfolio of market services means it is ideally positioned to play a role in the future development of European markets.
New York, US
Size (employees)
574 (est)
Euronext is headquartered in New York, US
Report incorrect company information

Euronext Office Locations

Euronext has offices in New York, Brussel, Amsterdam, Lisbon and in 2 other locations
New York, US (HQ)
11 Wall St
Brussel, BE
1 Markiesstraat
Courbevoie, FR
14 Place des Reflets
Amsterdam, NL
5 Beursplein
London, GB
Juxon House 100 St. Paul's Churchyard
Show all (6)
Report incorrect company information

Euronext Financials and Metrics

Euronext Financials

Market capitalization (31-Oct-2017)

3.5 b

Closing share price (31-Oct-2017)

Euronext's current market capitalization is €3.5 b.
Show all financial metrics
Report incorrect company information

Euronext News and Updates

Why I Sold Intelsat

European indices draw a blank after Euronext suffers "technical incident"

The opening levels across a number of European stock indices failed to appear to traders this morning after the Euronext exchange suffered a "technical incident". The glitch meant that France's benchmark index, the CAC 40, had no opening levels published – nor did the Netherlands' AEX, Belgium's …

UK pharma company Acacia Pharma chooses Euronext to conquer US market

Acacia Pharma, which is developing treatments for surgical and cancer patients, this month listed on Euronext stock exchange in Brussels, raising €40 million. The post UK pharma company Acacia Pharma chooses Euronext to conquer US market appeared first on

Euronext gets reprieve from new competition rule by blaming Brexit

Euronext has become the latest exchange to win a reprieve from a new "open access" competition rule, adding its name to the growing list which have blamed Brexit. The pan-European exchange was told by regulators in France, Belgium and Portugal that it could delay the implementation of an "open ac…
Show more
Report incorrect company information